company background image
AFMD

AffimedNasdaqGM:AFMD Stock Report

Market Cap

US$830.9m

7D

-6.9%

1Y

25.8%

Updated

02 Dec, 2021

Data

Company Financials +
AFMD fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

AFMD Stock Overview

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany.

Price History & Performance

Summary of all time highs, changes and price drops for Affimed
Historical stock prices
Current Share PriceUS$6.58
52 Week HighUS$11.74
52 Week LowUS$4.78
Beta2.55
1 Month Change-6.93%
3 Month Change-1.64%
1 Year Change25.81%
3 Year Change55.92%
5 Year Change220.98%
Change since IPO15.44%

Recent News & Updates

Oct 12

Affimed: Preparing For A Bullish 2022

Affimed reported mixed Q2 earnings that revealed more milestone payments from their partnerships. In addition, Affimed reported a healthy cash position that is expected to last into 2H of 2022. Affimed continues to move their wholly-owned and partnered pipeline programs. However, 2022 has several catalysts on the docket that could improve the company’s outlook. Despite the progress, the share price has remained under pressure and is moving closer to my buy area. Finally, I take a look at the charts to find a few opportunities to add to my "house money" position.

Aug 19
Does Affimed (NASDAQ:AFMD) Have A Healthy Balance Sheet?

Does Affimed (NASDAQ:AFMD) Have A Healthy Balance Sheet?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Shareholder Returns

AFMDUS BiotechsUS Market
7D-6.9%-1.4%-3.5%
1Y25.8%1.8%19.4%

Return vs Industry: AFMD exceeded the US Biotechs industry which returned 2% over the past year.

Return vs Market: AFMD exceeded the US Market which returned 17.8% over the past year.

Price Volatility

Is AFMD's price volatile compared to industry and market?
AFMD volatility
AFMD Average Weekly Movement7.6%
Biotechs Industry Average Movement8.8%
Market Average Movement6.1%
10% most volatile stocks in US Market14.9%
10% least volatile stocks in US Market2.4%

Stable Share Price: AFMD is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: AFMD's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2000153Adi Hoesshttps://www.affimed.com

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, which has completed Phase II clinical study of CD30-positive T-cell lymphoma, and hodgkin lymphoma (HL), as well as is in Phase II clinical trials for peripheral T-cell lymphoma, and transformed mycosis fungoides; that is in Phase I clinical study in combination with adoptive NK cells for CD30-postive lymphomas; and has completed Phase Ib clinical study in combination with anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed HL. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase I/IIa clinical trials for the treatment of advanced cancer patients; and AFM26, an innate cell-engaging bispecific antibody targeting B cell maturation antigen (BCMA) for the treatment of multiple myeloma.

Affimed Fundamentals Summary


Earnings & Revenue

Key profitability statistics from the latest earnings report
AFMD income statement (TTM)
Revenue€40.85m
Cost of Revenue€0
Gross Profit€40.85m
Expenses€90.16m
Earnings-€49.31m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.40
Gross Margin100.00%
Net Profit Margin-120.70%
Debt/Equity Ratio7.6%

How did AFMD perform over the long term?

See historical performance and comparison

Valuation

Is Affimed undervalued compared to its fair value and its price relative to the market?

5.35x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate AFMD's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate AFMD's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: AFMD is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: AFMD is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate AFMD's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: AFMD is overvalued based on its PB Ratio (5.4x) compared to the US Biotechs industry average (2.7x).


Future Growth

How is Affimed forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

0.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: AFMD is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: AFMD is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: AFMD is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: AFMD's revenue (26.4% per year) is forecast to grow faster than the US market (10.1% per year).

High Growth Revenue: AFMD's revenue (26.4% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if AFMD's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Affimed performed over the past 5 years?

-6.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: AFMD is currently unprofitable.

Growing Profit Margin: AFMD is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: AFMD is unprofitable, and losses have increased over the past 5 years at a rate of 6.9% per year.

Accelerating Growth: Unable to compare AFMD's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AFMD is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (11%).


Return on Equity

High ROE: AFMD has a negative Return on Equity (-36.84%), as it is currently unprofitable.


Financial Health

How is Affimed's financial position?


Financial Position Analysis

Short Term Liabilities: AFMD's short term assets (€203.3M) exceed its short term liabilities (€66.3M).

Long Term Liabilities: AFMD's short term assets (€203.3M) exceed its long term liabilities (€20.2M).


Debt to Equity History and Analysis

Debt Level: AFMD has more cash than its total debt.

Reducing Debt: AFMD's debt to equity ratio has reduced from 8.5% to 7.6% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: AFMD has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: AFMD has sufficient cash runway for 1.8 years if free cash flow continues to grow at historical rates of 3.4% each year.


Dividend

What is Affimed current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate AFMD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate AFMD's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AFMD's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AFMD's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of AFMD's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.8yrs

Average management tenure


CEO

Adi Hoess (60 yo)

10.25yrs

Tenure

€1,355,000

Compensation

Dr. Adi Hoess, M.D., Ph D., has been the Chief Executive Officer of Affimed N.V. since September 2011 and serves as its Managing Director and Member of Management Board. Dr. Hoess served as Chief Commercia...


CEO Compensation Analysis

Compensation vs Market: Adi's total compensation ($USD1.53M) is below average for companies of similar size in the US market ($USD2.31M).

Compensation vs Earnings: Adi's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: AFMD's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.


Board Members

Experienced Board: AFMD's board of directors are considered experienced (6.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 39.4%.


Top Shareholders

Company Information

Affimed N.V.'s employee growth, exchange listings and data sources


Key Information

  • Name: Affimed N.V.
  • Ticker: AFMD
  • Exchange: NasdaqGM
  • Founded: 2000
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$830.906m
  • Shares outstanding: 123.10m
  • Website: https://www.affimed.com

Number of Employees


Location

  • Affimed N.V.
  • Technologiepark
  • Im Neuenheimer Feld 582
  • Heidelberg
  • Baden-Württemberg
  • 69120
  • Germany

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/12/02 23:35
End of Day Share Price2021/12/02 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.